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The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predom-
inantly affecting Guinea, Sierra Leone, and Liberia, was prioritized by the World Health Organization in September 2014. In each of
these countries, nonrandomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea, enrolled 102 pa-
tients by 7 July 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have
included few patients. Although no efﬁcacy data are available yet, current ﬁeld experience supports the safety, acceptability, and fea-
sibility of CP as EVD treatment. Longer-term follow-up as well as data from nontrial settings and evidence on the scalability of the
intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the
advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.
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Convalescent blood or plasma transfusion has been used in clin-
ical settings for >100 years [1].Until the advent of antibiotic ther-
apy, it was widely used for a range of bacterial and viral diseases.
A recent meta-analysis suggests that it could have contributed to
an absolute reduction in mortality of around 20% during the
1918 inﬂuenza epidemic [2]. At present, hyperimmune globulin,
manufactured from convalescent donors’ plasma, is still em-
ployed as prophylaxis or treatment for certain infectious diseases
(eg, measles, diphtheria, polio, hepatitis A and B) [3]. Passive an-
tibody therapy is not a new intervention but a widely tested, safe,
and proven prophylactic and therapeutic intervention.
Over the last 10 years, convalescent plasma (CP) has been ex-
plored for the treatment of viral severe acute respiratory infec-
tions such as severe acute respiratory syndrome and (avian)
inﬂuenza. A recent meta-analysis identiﬁed 32 studies that indi-
cated, overall, a 75% reduced risk in the odds of mortality, par-
ticularly if CP was administered early after symptom onset [4,
5]. CP is currently being considered as treatment for Middle
East respiratory syndrome [6].
For hemorrhagic fevers, well-documented, relatively recent
experience stems from a randomized controlled trial comparing
CP (1 single unit of 500 mL) with normal plasma against Ar-
gentine hemorrhagic fever [7]. Mortality was 1.1% among the
91 patients who received CP compared to 16.5% in the 97 pa-
tients treated with normal plasma. Of interest, a delayed neuro-
logical condition was observed in some patients after CP
therapy, occurring several weeks after apparent cure. CP has
also been explored against the hemorrhagic disease Lassa
fever, with conﬂicting results [8–11].
The World Health Organization (WHO) guidelines recom-
mend both convalescent whole blood (CWB) and CP for use
against Ebola virus disease (EVD) [12]. During EVD outbreaks,
both are local and readily available sources of anti-EVD anti-
bodies. Blood transfusion is routinely done in all 3 high-trans-
mission countries involved in the current EVD outbreak;
however, plasma has numerous advantages in these settings.
Using apheresis, a single donor can give substantially more
CP, up to 10 mL/kg every 2 weeks, compared with 1 unit of
450 mL whole blood (approximately 250 mL plasma) every 3–
4 months for CWB; hence, more patients can be treated. CP can
be given intravenously over a much shorter time period (30
minutes vs 3–4 hours) and hence is less demanding for health-
care teams in Ebola treatment centers. The pathogen inactiva-
tion step during CP production increases the safety of the
intervention. CP transfusion is also safer with fewer transfusion
reactions; CP needs to be ABO compatible, but there is no need
for bedside cross-matching [13]. Additionally, CP can be stored
for much longer periods.
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Hyperimmune globulin has advantages compared with CWB
and CP, as it is a concentrated and puriﬁed product [14]. How-
ever, this product is presently not available against EVD, and
hence it has not been evaluated in the current Ebola outbreak.
Nevertheless, it represents an interesting longer-term potential
therapy, especially if the ongoing studies suggest efﬁcacy of CP.
Recombinant monoclonal antibodies are currently being evalu-
ated in Sierra Leone and Guinea [15], but will not be discussed
in detail given this article’s focus on convalescent blood
products.
EFFICACY
Animal Studies
The successful use of ZMapp (an antibody cocktail comprising
3 Ebola virus–speciﬁc recombinant monoclonal antibodies) for
treatment of EVD in non–human primate models, even when
administration is delayed until 5 days after a supralethal viral
challenge, provides proof of concept of antibody-based therapy
for EVD [16]. Similarly, the use of immunoglobulin fractions
from convalescent animals is effective for treating EVD in non-
human primates [17]. Earlier treatment attempts with mono-
clonal antibodies or immunoglobulins might have failed
because antibody concentrations were too low, antibodies had
too narrow a spectrum (eg, 1 monoclonal only), or because
treatment was not given repeatedly (ZMapp is given 3 times
[days 0, 3, 6]).
Early CWB studies with nonhuman primates failed to dem-
onstrate efﬁcacy when rhesus macaques were transfused imme-
diately after challenge [18]. There are no animal studies with
convalescent plasma against EVD. Key questions include
whether antibody titers are high enough in CP and CWB to
be effective, and if 1 single transfusion, as per current WHO
guidelines, is sufﬁcient. The exact kinetics of neutralizing anti-
bodies in convalescent donors and variation between individu-
als are currently not well described.
Clinical Data
Clinical data are limited. The most important study on CWB in
EVD reported on 8 individuals treated during the Kikwit out-
break in 1995; 7 survived [19]. However, this was an uncon-
trolled small study, with patients enrolled relatively late after
onset of symptoms. Moreover, several factors beyond an anti-
body-related effect could have contributed to the improved sur-
vival, such as improved hydration or the administration of other
blood components such as clotting factors. Moreover, a subse-
quent analysis after adjustment for age, sex, and number of days
since onset of symptoms showed no survival beneﬁt of CWB
[20]. One well-documented case occurred in 1976 when a lab-
oratory technician survived EVD after receiving 2 plasma trans-
fusions combined with interferon injections [21].
Several EVD patients (mainly expatriates) have been treated
with CWB, CP, or recombinant monoclonal antibodies during
the current outbreak [22–26]. However, most of these patients
received multiple anti-EVD interventions and high-quality sup-
portive care, so it is not possible to assess the efﬁcacy, if any, of
passive antibody transfer.
In conclusion, whereas the data on ZMapp provide proof of
concept, clinical data on and experience with convalescent blood
products for the treatment of EVD are very limited. Consequently,
WHO prioritized the need to evaluate CP in clinical trials, with the
aim to determine its efﬁcacy, safety, and feasibility. Notably, these
interventions can be organized by harnessing or increasing exist-
ing national capacities quickly within the affected countries, with-
out the complications or limitations associated with shipping
commercial products, which are often in limited supply.
Clinical Trials on CP in the 2014–2015 EVD Outbreak in West Africa
An overview of clinical trials is provided in Table 1. The Ebola-
Tx trial, in Conakry, Guinea, is designed to assess the feasibility,
safety, and efﬁcacy of CP against EVD [27]. Survival at 14 days
after transfusion of patients treated with CP plus supportive
care will be compared to that of patients receiving supportive
care alone, in an open-label phase 2/3, nonrandomized compar-
ative study. All eligible and consenting patients of any age with
conﬁrmed EVD (including pregnant women) are enrolled; exclu-
sion criteria are limited to contraindications for CP or patients
arriving in a close to terminal condition. Available ABO compat-
ible plasma is given, within 48 hours after diagnosis, on a ﬁrst-
come, ﬁrst-served basis. Patients for whom there is no available
compatible plasma are enrolled as concurrent controls, comple-
mented with historical controls. The ﬁrst plasma collection start-
ed on 9 February 2015, followed by the ﬁrst CP administration on
19 February 2015. As of 7 July 2015, 102 patients have been re-
cruited. The main analysis is planned when a cohort of 130 CP-
treated patients have reached day 14 posttransfusion. Due to the
ﬂuctuating number of new patients and the decline of the out-
break in Guinea, it is difﬁcult to estimate when this will happen.
The Ebola-CP consortium in Sierra Leone, which emerged
out of the Ebola-Tx initiative, is conducting a parallel study
in Freetown using a similar protocol, CRF, and data manage-
ment. The ﬁrst patient was recruited 19 March 2015 as a control
(no CP given); due to the declining outbreak in Sierra Leone, as
of 23 July 2015, 3 patients have received CP.
The EVD001 trial is a phase 1/2 pilot study with viral load
changes as the primary outcome [28]. Children and pregnant
women are excluded. The study started in Monrovia in Novem-
ber 2014 but subsequently closed due to the decline in caseload.
A total of 4 CP-treated patients and 2 controls were included.
The Ebola medical treatment team in the 34th Regiment
Hospital Freetown, Sierra Leone, has been administering
CWB, as per WHO guidance, for compassionate use from De-
cember 2014 to March 2015 (http://awoko.org/2014/12/09/
sierra-leone-news-convalescent-blood-treatment-started/). A
total of 52 patients opted for CWB transfusion with 24 included
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as controls. None of the ongoing clinical studies have reported
ﬁndings.
Designing trials, and recruiting patients, to evaluate CWB
and CP has been challenging. Only Ebola-Tx has achieved a rel-
atively high sample size (>80 CP-treated patients). The design
that would provide the best evaluation would be a randomized
trial in which one or other intervention would be compared
with control patients not receiving the intervention. However,
such randomized designs have proved unacceptable in the vola-
tile settings of the current Ebola outbreak, and researchers have
at the early stages resorted to nonrandomized study designs
[29]. All CP trials were designed to include concurrent control
patients. For example, in the Ebola-Tx trial, controls were to be
patients presenting when no ABO-compatible plasma was avail-
able. However, when the trial started, the supply of CP increased
signiﬁcantly and the number of patients decreased, resulting in
sufﬁcient supply of CP to treat nearly all patients. Consequently,
it will compare the mortality of treated patients with that of his-
torical controls, with the inherent possibility of biased compar-
isons. Key concerns in all trials regarded potential confounding
factors including variations in patient characteristics, Ebola vir-
ulence on presentation, and differences in standards of suppor-
tive care over time. For example, the systematic placement of
intravenous access lines in patients for CP treatment could en-
courage more aggressive intravenous hydration during the trial
period. How easy it will be to interpret the results of the trials
will depend, to a large extent, on the size of the mortality reduc-
tion, if any, associated with the intervention.
SAFETY
Plasma transfusion is considered a relatively safe procedure,
particularly if pathogen reduction is done. However, for use
as a treatment of EVD, there are additional considerations.
Safe production, storage, and distribution need to be organized
in the affected countries. Plasmapheresis technology needs to be
available or introduced, including quality-assured testing for
transfusion-transmissible infections and an effective cold
chain, all of which have been major challenges in the currently
affected West African countries. Although standards for blood
group typing are clearly deﬁned in the national guidelines,
errors can result from ﬁeld realities, such as lack of resources,
supervision, and poorly incentivized staff. Additionally,
weak systems of documentation can lead to poor or mistaken
identiﬁcation.
The infection control environment of Ebola treatment cen-
ters brings with it difﬁcult operational challenges, both for
care of patients and, in particular, for the implementation of
clinical research. Short and intermittent patient contact by
staff in protective clothing, with potentially confused patients,
is the norm. Therefore, mistakes are more likely to occur,
such as in patient identiﬁcation, labeling of blood tubes, and re-
quest forms during sample collection and packaging. Moreover,
introducing the procedure for blood group typing into already
overloaded EVD diagnostic laboratories might engender addi-
tional errors. This can potentially increase the risks of adverse
reactions due to preanalytical, analytical, or postanalytical er-
rors. These errors could potentially lead to severe reactions if
Table 1. Overview of Clinical Trials Conducted During the 2014–2015 Ebola Virus Disease Outbreak in West Africa
Characteristic/Feature Ebola-Tx Ebola-CP EVD001
Funder European Union Wellcome Trust Bill & Melinda Gates Foundation
Sponsor Institute of Tropical Medicine Antwerp University of Liverpool ClinicalRM
Study site Conakry, Guinea Freetown, Sierra Leone Monrovia, Liberia
Start date February 2015 April 2015 November 2014
Donor selection criteria PCR-confirmed EVD
>90 d after discharged cured (laboratory
confirmed)
PCR-confirmed EVD
>28 d after discharged cured
PCR-confirmed EVD
>28 d after discharged cured;
>60 d after EVD onset
Donor testing (infections) HIV, HBV, HCV, syphilis HIV, HBV, HCV, syphilis;
EVD PCR (plasma), antibodies (ELISA)
HIV, HBV, HCV, syphilis
EVD PCR (plasma), antibodies
(ELISA)
Plasma collection Apheresis & pathogen reduction (amotosalen) Apheresis & pathogen reduction (amotosalen) Apheresis & pathogen reduction
(amotosalen)
Study population Confirmed EVD—all ages including pregnant
women
Confirmed EVD—all ages including pregnant
women
Confirmed EVD—adults only
(>18 y)
Study design/phase Phase 2/3 Phase 2/3 Phase 1/2 pilot study
Intervention Two units (200–250 mL each, different donors)
given consecutively
One unit of 500 mL originating from 1 single
donor
Two units (100 mL each, different
donors) repeated at 48 h as
indicated
Primary outcome Survival at 14 d Survival at 14 d Change in VL and EV antibody
levels
Secondary outcomes (1) survival at 30 d; (2) serious adverse
reactions; (3) change in VL; (4) safety risks in
health workers; (5) risk factors for mortality
(1) survival at 30 d; (2) serious adverse
reactions; (3) VL and EV IgG antibody levels
over time; (4) safety risks in health workers
(1) survival at discharge; (2) safety;
(3) VL and EV IgG antibody
levels over time
Abbreviations: CP, convalescent plasma; EV, Ebola virus; EVD, Ebola virus disease; ELISA, enzyme-linked immunosorbent assay; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; IgG, immunoglobulin G; PCR, polymerase chain reaction; VL, viral load.
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ABO-incompatible plasma with high titers of hemolysins were
administered.
The ability to monitor patients for and to react to severe,
acute adverse reactions is clearly limited by the environment
of many Ebola treatment centers. Some (severe) transfusion re-
actions might erroneously be attributed to EVD [29, 30]. For in-
stance, respiratory difﬁculties, often seen during EVD, might be
due to transfusion-related acute lung injury. Patient manage-
ment options for adverse events may also be limited.
It has been suggested for a number of viruses, including
Ebola, that the transfer of antibodies might enhance pathoge-
nicity, possibly by antibody-enhanced cell entry [31]. Although
more recent studies have suggested that this is unlikely to have
clinical signiﬁcance, it still requires special attention and careful
evaluation when employing CP, regardless of whether it is for
clinical trials or compassionate use [32].
No severe adverse reactions or safety risks for healthcare staff
have been noted in the Ebola-Tx trial by 7 July 2015. While this
suggests that CP can be employed safely for EVD treatment, the
use of such treatment, if found efﬁcacious, should be evaluated
in noncontrolled settings before introducing it as a standard of
care in public health facilities.
FEASIBILITY AND ACCEPTABILITY
The quality of blood transfusion services in many West African
countries is generally poor, and in many countries, plasma pro-
duction is not routinely performed [33]. During the EVD out-
break, effective plasmapheresis teams were assembled relatively
quickly, mainly in mobile plasma units or “plasma mobiles”
(http://www.gatesfoundation.org/Media-Center/Press-Releases/
2014/11/Support-to-Ebola-Affected-Countries-Announcement),
and national blood transfusion teams trained. This was made
possible by the substantial funding made available through in-
ternational research consortia. As the situation dictated an
emergency response, the plasmapheresis material introduced
for use in the present trials is unlikely to be an optimal choice
for the concerned national transfusion centers. A transition to
simpler, nonautomated systems might be indicated. Further-
more, pathogen reduction is an expensive procedure and un-
likely to be a priority for resource-constrained settings, where
the prerogative is the provision of safe basic blood banking ser-
vices. The experience of the present trials, which has identiﬁed
the need to further improve the overall quality of blood banking
centers in all 3 countries, should result in longer-term capacity-
building projects once the outbreak is contained.
The use of convalescent blood products is further complicat-
ed by the requirement to carefully and properly manage the en-
gagement of Ebola survivors, who are often stigmatized in their
communities. In many West African countries there is reticence
toward blood collection, donation, and transfusion, based on
superstitions and beliefs in the community [34, 35]. Experience
during the 2014–2015 outbreak suggests that if there are appro-
priate community consultations and discussions, there is a rea-
sonable acceptability among plasma donors, surviving patients,
Table 2. Advantages and Disadvantages of Different Sources of Antibodies Against Ebola Virus Disease
Characteristic/Feature Convalescent Whole Blood Convalescent Plasma Hyperimmune Globulinsa
Recombinant Monoclonal
Antibodies
Availability Survivors in affected
countries can act as
source
Survivors in affected
countries can act as
source
Currently not available, requires
high amounts of CP or
production in animals
Limited; potential for more
efficient production methods
Accessibility in affected
low-income countries
Produced within and by the
affected countries
Produced within and by the
affected countries
Not clear how it will be marketed
and how prioritization will be
decided
Not clear how it will be marketed
and how prioritization will be
decided
Collection/production 1 donation/3–4 mo (10 mL/
kg)
1 donation/2 wk (10 mL/kg) One production plant in Africa US (1) and Chinese (1) company
Storage >1 mo (2°C–6°C) 3 y (−30°C) 2–3 y (4°C) Long-term (−20°C)
Administration IV (4 h) IV (20–40 min) IV (variable, usually <1 hour) or IM IV (6–12 h) or subcutaneous
Potential side effects +++(+)b +(+)b +b +++(?)b
Risk with ABO
incompatibility
++++b +b NA NA
Costs/affordability +b ++b +++b ++++b
Acceptability in EVD
context
Well-known procedure
Current data suggest
reasonable donor
acceptability
New procedure;
Current data suggest
reasonable donor
acceptability
Presumably good Presumably good
Activity against
circulating virus
CWB produced during
outbreak likely effective
CP produced during
outbreak likely effective
Activity to be shown against
viruses causing new outbreaks
Activity to be shown against
viruses causing new outbreaks
Production time Short (<1 d) once donors
identified
Short (days) once donors
identified
Months Months
Abbreviations: CP, convalescent plasma; CWB, convalescent whole blood; EVD, Ebola virus disease; IM, intramuscular; IV, intravenous; NA, not applicable.
a Most efforts currently focused on human sources of antibodies, but animal production is under exploration as well.
b +: Very low; ++: Low; +++: Moderate; +++(+): Moderate to high; ++++: High; (?): Substantial uncertainty given limited clinical experience.
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and their family members, at least in the short term. However, a
better understanding of plasma donor motivation is required to
ascertain whether possible degrees of coercion have occurred. In
all 3 high-transmission countries, EVD survivors have orga-
nized themselves into survivor associations. Although this has
probably substantially eased donor mobilization, more in-
depth assessments of their potential role are merited.
Other key concerns include conﬁdentiality and privacy, espe-
cially if members of the survivors association are involved in the
recruitment process. Additionally, confronting individuals re-
cently recovered from EVD with positive serological tests for
other infections can have negative consequences. Lack of free
access to care for infections such as hepatitis B and C further
compounds the situation [36]. Hence, longer follow-up and
more in-depth anthropological assessments among plasma do-
nors and patients are required to further document the accept-
ability and feasibility of CP as EVD treatment. It has been
suggested that involving survivors as donors in a potentially
life-saving treatment could support their social reintegration
and reduce stigma, but evidence for this is currently lacking.
SCALABILITY
Although hopefully there will not be another Ebola outbreak on
the scale of the present one, it would be possible to stockpile
plasma for emergency use. There are currently >15 000 Ebola
survivors in the 3 high-transmission countries. A single donor,
donating 600 mL every 2 weeks, could provide sufﬁcient plasma
to treat around 35 patients. With 500 regular donors (approxi-
mately 3% of the potential total), a total of 17 500 treatments
would potentially be available. Prequaliﬁcation of donors with
high titers of neutralizing antibodies would make the process
most efﬁcient. Such scaling up of CP would require either de-
centralized plasma production or safe transport and storage of
CP from a central location to more remote areas.
Blood transfusion regulations recommend that people who
received a blood transfusion should not be permitted to donate
blood for 12 months after the date of transfusion, mainly related
to the risk of pathogen transmission. Applying this to EVD sur-
vivors following CP treatment would seriously reduce the donor
pool. However, if CP is shown to have a substantial effect, the
beneﬁts of using such patients as donors would probably out-
weigh potential risks. It should also be conﬁrmed that CP-treated
patients develop sufﬁcient level of neutralizing antibodies against
the virus, particularly if treated early in the disease course.
The logical next step is to produce hyperimmune globulins
from the donated plasma, and several initiatives are focusing
on this. As puriﬁed and concentrated products, hyperimmune
globulins are generally considered to be safer and with higher,
less variable antibody titers than CP (Table 2). They can also be
stored for prolonged periods. Animal production of hyperim-
mune globulins is also under exploration (http://www.faben
techcom/technologie/technology/). Pending the building up of
such expertise within Africa, production could be outsourced.
CONCLUSIONS
Current ﬁeld experience supports the use of CP against EVD as
acceptable, feasible, and safe. Efﬁcacy data are pending. In con-
sideration of the study design limitations described in this arti-
cle, these trials may not yield deﬁnitive data on the extent to
which such treatment reduces case fatality rates. However, it
is expected that they will, at minimum, provide some indication
of the utility of CP and the challenges in delivering such treat-
ment, in future trials. Additional research on CP, hyperimmune
globulins, and monoclonal antibodies in animal and clinical
studies is required to identify the optimal treatment regimen
and better understand the mechanism of action.
Long-term studies are also required to document better the
feasibility and acceptability of CP donation outside of a research
setting, to assess the willingness of survivors to become CP do-
nors and to identify any negative immunological, medical, or
psychosocial effects of repeated CP donations. Longer follow-
up of CP treated patients is also indicated to detect late adverse
events.
Although hyperimmune globulins and recombinant mono-
clonal antibodies have several advantages, the use of CP sourced
from within an outbreak is arguably the most readily available
source of anti-EVD antibodies and will always have the advan-
tage that it is likely to be active against the circulating strain. In
each new outbreak, available hyperimmune globulins or mono-
clonal antibodies will ﬁrst have to be evaluated against the caus-
ative strain and possibly followed by the production of a new
product, all of which takes time. Until the advent of potent,
safe, affordable, and effective antivirals, and the development
of effective vaccines, the use of convalescent blood products
should remain part of the potential response to EVD.
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